On February 3, 2026, we participated in the institutional presentation event of “REVALORE: Recommendations on the Inclusion of Social Value in the Evaluation of Medicines”, held at the Congress of Deputies in Madrid.
The event presented the REVALORE report, promoted by Roche and carried out by Theorema4H in collaboration with BioInnova Consulting, and discussed how to systematically incorporate social value into the evaluation and funding of medicines, beyond clinical benefit and budget impact.
In the opening session, Agustín Santos (President of the Health Committee) advocated for separating price and value, placing “social utility” at the center of the debate. Carlos Martín Saborido (Director of the Health Technology Assessment Agency at the Carlos III Health Institute) described the limitations of the current model and highlighted three underrepresented dimensions: equity and social cohesion, positive externalities, and patient burden.
In the methodological panel, Jaime Espín (Andalusian School of Public Health) criticized “silos” and the lack of social data in clinical trials; Alfredo García-Layana (President of SERV) emphasized that not everything important is reflected in traditional clinical indicators; Javier de Castro (President of SEOM) called for the inclusion of functionality and quality of life; Isolina Riaño (pediatric endocrinologist and Vice President of the Spanish Ethics Committee) noted that the impact of disease goes far beyond the hospital setting and advocated for incorporating ethical reflection into decision-making due to the prolonged burden on families; and Andoni Lorenzo (President of the Spanish Patients’ Forum) called for structured patient participation with real weight in decision-making.
The political panel, moderated by Rubén Moreno, addressed territorial inequalities and the need for data transparency. The session was closed by Patrick Wallach (General Manager of Roche Farma Spain), who called for clear governance and the removal of administrative barriers.
You can consult the full REVALORE report here:
https://theorema4h.com/publicaciones/reflexion-estrategica-sobre-el-valor-social-en-la-evaluacion-de-medicamentos/
